# Ombitasvir/ Paritaprevir / Ritonavir Plus Ribavirin in Management HCV and End-stage Kidney Disease

> **NCT03499639** · PHASE4 · COMPLETED · sponsor: **Assiut University** · enrollment: 110 (actual)

## Conditions studied

- End-stage Renal Disease
- HCV Coinfection

## Interventions

- **DRUG:** Ombitasvir / Paritaprevir / Ritonavir /Ribavirin Oral Tablet

## Key facts

- **NCT ID:** NCT03499639
- **Lead sponsor:** Assiut University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-01
- **Primary completion:** 2018-08-01
- **Final completion:** 2018-09-30
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2020-01-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03499639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03499639, "Ombitasvir/ Paritaprevir / Ritonavir Plus Ribavirin in Management HCV and End-stage Kidney Disease". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03499639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*